- Home
- Healthcare professionals
- ACE Clinical Guidances (ACGs)
- Type 2 diabetes mellitus — personalising management with non-insulin medications
Published
Type 2 diabetes mellitus — personalising management with non-insulin medications
Endocrine and metabolic
ACG
17 May 2023
Published on 17 May 2023
Last Updated on 17 May 2023
Registered doctors, pharmacists and nurses may claim 1 Continuing Medical Education (CME)/Continuing Professional Education (CPE) point under category 3A/ category V-B for reading each ACG.
Resources
This ACE Clinical Guidance (ACG) focuses on optimising management of type 2 diabetes mellitus (T2DM) by personalising selection of non-insulin T2DM medications based on patient comorbidities and risk factors, in particular cardiovascular and renal factors.
This ACG replaces the 2017 ACG “Oral glucose-lowering agents in type 2 diabetes mellitus – an update”.
ACG Recommendations
Assess the patient’s glycaemic control and risk of adverse cardiorenal outcomes.
Select and adjust T2DM medication(s) based on the patient’s glycaemic control and their risk of adverse cardiorenal outcomes.
Consider metformin as first-line T2DM medication.
Consider prescribing an SGLT2 inhibitor or GLP-1 RA for patients with T2DM who need to reduce their risk of adverse cardiorenal outcomes.
Adopt a patient-centred approach to make shared decisions on T2DM management.
Educate patients with T2DM on sustained lifestyle intervention, medication adherence, and regular review.
Review all patients with T2DM regularly, including treatment response and complication screening.